What is the equity of Novocure this year?
Novocure has equity of 360.18 M USD this year.
Novocure Equity 2025
Novocure Equity
360.18 M USD
Ticker
NVCR
ISIN
JE00BYSS4X48
WKN
A140ML
In 2025, Novocure's equity was 360.18 M USD, a -0.64% increase from the 362.5 M USD equity in the previous year.
Novocure Aktienanalyse
What does Novocure do?
Novocure Ltd. is a global scientific-based company that was founded in Israel in 2000. Its focus was originally on researching and developing tumor therapies. Since then, Novocure has become one of the leading companies in cancer research and treatment, specializing in the development of innovative cancer therapies. The business model of Novocure is based on developing powerful and innovative treatment methods for a variety of cancer types, including brain, pancreatic, prostate, and lung cancer. The company is committed to developing new cancer treatments that improve the lives of patients and meet their needs. Novocure also offers a wide range of products, including several treatment options based on the use of electric fields. These electric fields can specifically target the tumor and inhibit cell division without damaging the surrounding healthy tissue. This innovative technology is also called "tumor therapeutic fields" (TTF). TTF is a non-invasive procedure that is able to destroy cancer cells and inhibit the growth of cancer cells using targeted radio waves. The company also has its own research and development department dedicated to the development of innovative cancer therapies. In collaboration with numerous leading medical experts and researchers worldwide, Novocure advances cancer treatment research and development, striving to improve the treatment of cancer patients worldwide. Novocure operates three main divisions: Onco-Support, Onco-Centers, and Medical Research. The Onco-Support division offers specialized services to patients, such as training on the use of TTF devices, assistance with insurance issues, facilitating access to TTF devices, and help with setting up TTF devices. The Onco-Centers division operates various clinics specialized in the treatment of skin and brain cancer. Here, patients can benefit from the use of TTF devices and receive this therapy from experienced specialists. The Onco-Centers also provide tailored support and counseling for the needs of patients. The Medical Research division of the company also conducts research and development activities in the field of cancer therapies. Here, new therapies and procedures for cancer treatment are explored and developed, with a particular focus on the application of TTF devices. The goal of this research is to develop innovative cancer treatments that improve the lives of cancer patients and give them hope for a better future. Overall, Novocure Ltd. is an innovative and customer-oriented company dedicated to the treatment of cancer patients. The company invests heavily in research and development to develop innovative therapies and products that meet the high needs of cancer patients. The use of TTF technology is a significant step in cancer treatment, and Novocure Ltd. is leading the global development in this regard. Novocure ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Novocure's Equity
Novocure's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Novocure's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Novocure's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Novocure's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Novocure’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Novocure stock
What was the equity of Novocure compared to the previous year?
The equity of Novocure has increased/decreased by -0.64% decreased compared to the previous year.
What impact does a high equity have on investors of Novocure?
A high equity is advantageous for investors of Novocure as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Novocure?
A low equity can be a risk for investors of Novocure, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Novocure affect the company?
An increase in equity of Novocure can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Novocure affect the company?
A reduction in equity of Novocure can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Novocure?
Some factors that can affect the equity of Novocure include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Novocure so important for investors?
The equity of Novocure is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Novocure take to change the equity?
To change equity, Novocure can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Novocure pay?
Over the past 12 months, Novocure paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novocure is expected to pay a dividend of 0 USD.
What is the dividend yield of Novocure?
The current dividend yield of Novocure is .
When does Novocure pay dividends?
Novocure pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novocure?
Novocure paid dividends every year for the past 0 years.
What is the dividend of Novocure?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novocure located?
Novocure is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novocure kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novocure from 10/5/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2025.
When did Novocure pay the last dividend?
The last dividend was paid out on 10/5/2025.
What was the dividend of Novocure in the year 2024?
In the year 2024, Novocure distributed 0 USD as dividends.
In which currency does Novocure pay out the dividend?
The dividends of Novocure are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Novocure
Our stock analysis for Novocure Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novocure Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.